Belgium-based drug discovery and development company Apitope has regained global rights to its compound, ATX-MS-1467.
The potentially disease-modifying therapy ATX-MS-1467 is used to treat multiple sclerosis (MS) and completed a Phase II clinical trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company said it will regain all rights and clinical data associated with the compound under the agreement with Merck.
Apitope CEO Dr Keith Martin said: “We believe ATX-MS-1467 has enormous potential for treating MS patients. We are pleased to be regaining the rights to the compound, as well as the clinical data.
“This will provide us with greater flexibility and control in the clinical development of ATX-MS-1467. We are now able to pursue new business collaborations to enable the further development of this promising treatment.
“We appreciate the efforts made by the Merck KGaA, Darmstadt, Germany, team members in advancing this programme to date.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe Phase I clinical trial was completed in six patients with secondary progressive MS (SPMS) and a second Phase I trial in 43 relapsing MS patients.
Following the examination of the MRI results including new gadolinium-enhancing and total gadolinium-enhancing [Gd+] lesions, a fall of 78% in the number of Gd+ brain lesions was found in patients with relapsing MS treated with intradermal injection of ATX-MS-1467.
Enrolment last year in a Phase IIa clinical trial of ATX-MS-1467 in relapsing multiple sclerosis was concluded.
The outcome of the study is expected in the fourth quarter of this year.
